Enozertinib (ORIC-114), a highly selective, brain penetrant EGFR and HER2 inhibitor, in EGFR Exon 20 mutant NSCLC: randomized dose optimization and CNS activity
John, T. Mohindra, N. Hong, M. H. Lee, K. Leighl, N. B. Rotow, J. Alder, L. Dziadziuszko, R. Krebs, M. G. Sabari, J.
John, T.
Mohindra, N.
Hong, M. H.
Lee, K.
Leighl, N. B.
Rotow, J.
Alder, L.
Dziadziuszko, R.
Krebs, M. G.
Sabari, J.
Abstract
Description
Date
2025
Publisher
Collections
Keywords
Type
Article
Citation
John T, Mohindra N, Hong MH, Lee K, Leighl NB, Rotow J, et al. Enozertinib (ORIC-114), a highly selective, brain penetrant EGFR and HER2 inhibitor, in EGFR Exon 20 mutant NSCLC: randomized dose optimization and CNS activity. Annals of Oncology. 2025 DEC;36.